Clinical Trial: The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)

Study Status: Terminated
Recruit Status: Terminated
Study Type: Observational

Official Title: The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)

Brief Summary: Our aim in this study is to investigate the potential role of serum ProCT as an early diagnostic marker and later prognostic indicator for VAP.

Detailed Summary: Ventilator-associated pneumonia (VAP), a bacterial infection that develops after 48 hours or more of intubation, is associated with high morbidity and mortality. Rapid identification of VAP is required to improve survival and to reduce avoidable treatment-associated side effects. Procalcitonin (ProCT), a blood test, is a reasonably specific marker of bacterial infection and its level increases early in sepsis. In this study, a ProCT serum level will be measured in 50 patients with clinically suspected VAP. We aim to show that the ProCT level will be high early in VAP and will stay high in patients with poor prognosis. This will help to address the potential role of ProCT as part of early diagnosis and management of VAP.
Sponsor: McGill University Health Center

Current Primary Outcome: Cases with VAP and high ProCT and Cases with Non-VAP and Low ProCT [ Time Frame: Retrospective chart review after results are available ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: McGill University Health Center

Dates:
Date Received: July 6, 2007
Date Started: July 2007
Date Completion:
Last Updated: December 17, 2009
Last Verified: December 2009